Cell-Based Therapy for Fibrosing Interstitial Lung Diseases, Current Status, and Potential Applications of IPSC-Derived Cells

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2024 Jun 19

PMID 38891026

Authors

Yusuke Nakamura

Seiji Niho

Yasuo Shimizu

Affiliations

Soon will be listed here.

Abstract

Fibrosing interstitial lung diseases (FILDs), e.g., due to idiopathic pulmonary fibrosis (IPF), are chronic progressive diseases with a poor prognosis. The management of these diseases is challenging and focuses mainly on the suppression of progression with anti-fibrotic drugs. Therefore, novel FILD treatments are needed. In recent years, cell-based therapy with various stem cells has been investigated for FILD, and the use of mesenchymal stem cells (MSCs) has been widely reported and clinical studies are also ongoing. Induced pluripotent stem cells (iPSCs) have also been reported to have an anti-fibrotic effect in FILD; however, these have not been as well studied as MSCs in terms of the mechanisms and side effects. While MSCs show a potent anti-fibrotic effect, the possibility of quality differences between donors and a stable supply in the case of donor shortage or reduced proliferative capacity after cell passaging needs to be considered. The application of iPSC-derived cells has the potential to overcome these problems and may lead to consistent quality of the cell product and stable product supply. This review provides an overview of iPSCs and FILD, followed by the current status of cell-based therapy for FILD, and then discusses the possibilities and perspectives of FILD therapy with iPSC-derived cells.

References

Aguilar S, Scotton C, McNulty K, Nye E, Stamp G, Laurent G . Bone marrow stem cells expressing keratinocyte growth factor via an inducible lentivirus protects against bleomycin-induced pulmonary fibrosis. PLoS One. 2009; 4(11):e8013. PMC: 2779453. DOI: 10.1371/journal.pone.0008013. View

Lee H, Jeong O, Park H, Lee S, Bok E, Kim M . Promising Therapeutic Effects of Embryonic Stem Cells-Origin Mesenchymal Stem Cells in Experimental Pulmonary Fibrosis Models: Immunomodulatory and Anti-Apoptotic Mechanisms. Immune Netw. 2024; 23(6):e45. PMC: 10767550. DOI: 10.4110/in.2023.23.e45. View

Johannson K, Chaudhuri N, Adegunsoye A, Wolters P . Treatment of fibrotic interstitial lung disease: current approaches and future directions. Lancet. 2021; 398(10309):1450-1460. DOI: 10.1016/S0140-6736(21)01826-2. View

Flaherty K, Wells A, Cottin V, Devaraj A, Walsh S, Inoue Y . Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med. 2019; 381(18):1718-1727. DOI: 10.1056/NEJMoa1908681. View

Parker M, Rossi D, Peterson M, Smith K, Sikstrom K, White E . Fibrotic extracellular matrix activates a profibrotic positive feedback loop. J Clin Invest. 2014; 124(4):1622-35. PMC: 3971953. DOI: 10.1172/JCI71386. View

Leong S, Bos S, Lordan J, Nair A, Fisher A, Meachery G . Lung transplantation for interstitial lung disease: evolution over three decades. BMJ Open Respir Res. 2023; 10(1). PMC: 9980330. DOI: 10.1136/bmjresp-2022-001387. View

Zhou Q, Ye X, Sun R, Matsumoto Y, Moriyama M, Asano Y . Differentiation of mouse induced pluripotent stem cells into alveolar epithelial cells in vitro for use in vivo. Stem Cells Transl Med. 2014; 3(6):675-85. PMC: 4039451. DOI: 10.5966/sctm.2013-0142. View

Averyanov A, Koroleva I, Konoplyannikov M, Revkova V, Lesnyak V, Kalsin V . First-in-human high-cumulative-dose stem cell therapy in idiopathic pulmonary fibrosis with rapid lung function decline. Stem Cells Transl Med. 2019; 9(1):6-16. PMC: 6954714. DOI: 10.1002/sctm.19-0037. View

Lee S, Jang A, Kim Y, Cha J, Kim T, Jung S . Modulation of cytokine and nitric oxide by mesenchymal stem cell transfer in lung injury/fibrosis. Respir Res. 2010; 11:16. PMC: 2827393. DOI: 10.1186/1465-9921-11-16. View

10.

Gad E, Salama A, El-Shafie M, Arafa H, Abdelsalam R, Khattab M . The Anti-fibrotic and Anti-inflammatory Potential of Bone Marrow-Derived Mesenchymal Stem Cells and Nintedanib in Bleomycin-Induced Lung Fibrosis in Rats. Inflammation. 2019; 43(1):123-134. DOI: 10.1007/s10753-019-01101-2. View

11.

Bayati P, Taherian M, Soleimani M, Farajifard H, Mojtabavi N . Induced pluripotent stem cells modulate the Wnt pathway in the bleomycin-induced model of idiopathic pulmonary fibrosis. Stem Cell Res Ther. 2023; 14(1):343. PMC: 10685538. DOI: 10.1186/s13287-023-03581-4. View

12.

Kelly M, Kolb M, Bonniaud P, Gauldie J . Re-evaluation of fibrogenic cytokines in lung fibrosis. Curr Pharm Des. 2003; 9(1):39-49. DOI: 10.2174/1381612033392341. View

13.

Lan Y, Choo K, Chen C, Hung T, Chen Y, Hsieh C . Hypoxia-preconditioned mesenchymal stem cells attenuate bleomycin-induced pulmonary fibrosis. Stem Cell Res Ther. 2015; 6:97. PMC: 4487587. DOI: 10.1186/s13287-015-0081-6. View

14.

Huleihel L, Sellares J, Cardenes N, Alvarez D, Faner R, Sakamoto K . Modified mesenchymal stem cells using miRNA transduction alter lung injury in a bleomycin model. Am J Physiol Lung Cell Mol Physiol. 2017; 313(1):L92-L103. PMC: 5538868. DOI: 10.1152/ajplung.00323.2016. View

15.

Rojas M, Xu J, Woods C, Mora A, Spears W, Roman J . Bone marrow-derived mesenchymal stem cells in repair of the injured lung. Am J Respir Cell Mol Biol. 2005; 33(2):145-52. PMC: 2715309. DOI: 10.1165/rcmb.2004-0330OC. View

16.

Serrano-Mollar A, Gay-Jordi G, Guillamat-Prats R, Closa D, Hernandez-Gonzalez F, Marin P . Safety and Tolerability of Alveolar Type II Cell Transplantation in Idiopathic Pulmonary Fibrosis. Chest. 2016; 150(3):533-43. DOI: 10.1016/j.chest.2016.03.021. View

17.

Ntolios P, Manoloudi E, Tzouvelekis A, Bouros E, Steiropoulos P, Anevlavis S . Longitudinal outcomes of patients enrolled in a phase Ib clinical trial of the adipose-derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis. Clin Respir J. 2018; 12(6):2084-2089. DOI: 10.1111/crj.12777. View

18.

Liu Y, Li L, Yang C, Lu K, Huang C, Kao K . Suppressing NF-κB and NKRF Pathways by Induced Pluripotent Stem Cell Therapy in Mice with Ventilator-Induced Lung Injury. PLoS One. 2013; 8(6):e66760. PMC: 3694116. DOI: 10.1371/journal.pone.0066760. View

19.

Takahashi K, Yamanaka S . Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006; 126(4):663-76. DOI: 10.1016/j.cell.2006.07.024. View

20.

Winters N, Burman A, Kropski J, Blackwell T . Epithelial Injury and Dysfunction in the Pathogenesis of Idiopathic PulmonaryFibrosis. Am J Med Sci. 2019; 357(5):374-378. PMC: 6481315. DOI: 10.1016/j.amjms.2019.01.010. View